Pham Quang X sold $2K of CVKD
Pham Quang X (CEO and Chairman) sold 303 shares of Cadrenal Therapeutics, Inc. (CVKD) at $5.01 on 2026-05-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The CEO/Chairman’s disclosed open-market sale (303 shares) on a pre-arranged 10b5-1 plan provides incremental sentiment information but is not a fundamental catalyst by itself.
Market read
Insider selling disclosure may slightly pressure sentiment, but 10b5-1 framing usually limits interpretive weight.
What to watch
Traders may overreact to small Form 4 sales; the more informative signal is whether there are repeated sales, purchases, or changes in trading patterns around major catalysts.
Background
The article is an SEC Form 4 insider transaction disclosure for Cadrenal Therapeutics, Inc. (CVKD).
Ticker impact
CEO/Chairman Pham Quang X sold 303 shares of Cadrenal Therapeutics on a 10b5-1 plan, disclosing direct insider selling at ~$5.01/share.
Likely limited near-term price impact; watch for follow-on insider activity or volume changes.
The filing is a routine Form 4 insider transaction with a stated 10b5-1 plan; the disclosed size/value is small relative to typical liquidity, so incremental impact is usually muted.
Market effects
No sector-wide read-through; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
Because it’s explicitly a 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than negative fundamentals.
Key entities
- issuerCadrenal Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderPham Quang X
CEO and Chairman; reported a 10b5-1 open-market sale of 303 shares.
